FLEXIBZUMAB

Serial Number 90792277
606

Registration Progress

Application Filed
Jun 24, 2021
Under Examination
Jun 21, 2022
Approved for Publication
Apr 26, 2022
Published for Opposition
Apr 26, 2022
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: FLEXIBZUMAB
Previous Owner: Elastrin Therapeutics Inc.
Classes: 005

Trademark Image

FLEXIBZUMAB

Basic Information

Serial Number
90792277
Filing Date
June 24, 2021
Published for Opposition
April 26, 2022
Abandonment Date
July 28, 2025
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Jul 28, 2025
Classes
005

Rights Holder

Elastrin Therapeutics Inc.

03
Address
1 LAUREL BRANCH LN
SIMPSONVILLE, SC 29681

Ownership History

Elastrin Therapeutics Inc.

Original Applicant
03
SIMPSONVILLE, SC

Elastrin Therapeutics Inc.

Owner at Publication
03
SIMPSONVILLE, SC

Legal Representation

Attorney
Joyce von Natzmer

USPTO Deadlines

All Deadlines Cleared

All 1 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

39 events
Date Code Type Description Documents
Jul 28, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Jul 28, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Mar 28, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 28, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Dec 11, 2024 EXT5 S SOU EXTENSION 5 FILED Loading...
Mar 28, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Dec 11, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 20, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 20, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Jun 20, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Jun 20, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Dec 14, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 12, 2023 EX3G S SOU EXTENSION 3 GRANTED Loading...
Dec 12, 2023 EXT3 S SOU EXTENSION 3 FILED Loading...
Dec 12, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 22, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jun 20, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Jun 20, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Jun 20, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 1, 2023 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY Loading...
Dec 15, 2022 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Dec 13, 2022 EX1G S SOU EXTENSION 1 GRANTED Loading...
Dec 13, 2022 EXT1 S SOU EXTENSION 1 FILED Loading...
Dec 13, 2022 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 21, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Apr 26, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 26, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 6, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 22, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 22, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Mar 22, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Mar 22, 2022 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Mar 22, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Mar 16, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Dec 13, 2021 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Dec 13, 2021 ALIE A ASSIGNED TO LIE Loading...
Dec 8, 2021 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Sep 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 28, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations, namely, a drug delivery system comprising monoclonal antibodies for guiding therapeutic agents to a target tissue; therapeutic pharmaceutical for the treatment of cardiovascular diseases, high blood pressure, arteriosclerosis, aneurysms, diabetes, kidney diseases, and chronic obstructive pulmonary disease (COPD), the forgoing containing monoclonal antibodies; monoclonal antibodies for medical and veterinary purposes; monoclonal antibody preparations for therapeutic purposes; monoclonal antibodies for targeting drugs to calcified tissue for therapeutic purposes

Classification

International Classes
005